{
    "id": "3mrbkei56thnqpcdhaoq4sesspvp7pqp",
    "title": "Systems Pharmacology: An Industry Perspective",
    "info": {
        "author": [
            "Matthias Machacek, LYO-X GmbH"
        ],
        "published": "July 21, 2014",
        "recorded": "May 2014",
        "category": [
            "Top->Medicine"
        ]
    },
    "url": "http://videolectures.net/mdo2014_machacek_systems_pharmacology/",
    "segmentation": [
        [
            "Good afternoon everyone.",
            "I'd like to thank the organizers very much.",
            "Give me the opportunity here to present at this conference in front of this audience.",
            "So I think it's going to be a little bit on uphill talk for me because I'm going to present an industry perspective on an in silico approach on biotherapeutics, so it's three Rs.",
            "I would think that this audience is probably a bit further away to what I heard this morning, so let's see how how this will work."
        ],
        [
            "If we look at the current landscape in drug development or the IT really broadened from the original small molecule approach and what we have of course antibodies but also that sort development to continue to grow, we have different approaches.",
            "We have BI specifics with the different derivatives, we have, fat fragments, single chain of fees we have non aborted so.",
            "Immune components from other animal species which might have which might have other favorable properties.",
            "We of course also have S RNA based therapeutics or cell based therapeutics, so the whole thing tremendously grew in the past years.",
            "And what actually?",
            "What is a great achievement?",
            "And development is also a challenge.",
            "At the same time.",
            "Because the question always, you know, given given a tour."
        ],
        [
            "Git or a goal we like to achieve what is then the the right approach to land on on the target, literally on the target molecule.",
            "We want to want to do.",
            "We want to focus on.",
            "Now you suddenly have a big choice of different approaches, and of course what I want.",
            "Forgot to mention, we have also the combination of antibodies with more small molecules with toxins.",
            "Unable to drag Queen if it's for an therapeutic approach to cancer.",
            "And of course, you know you won't be.",
            "It will not be possible to screen through all the different formats to screen all the different properties of each of these formats to figure out what the best approach is, so there needs to be some better, some more rational approach in selecting, developing and selecting the right molecule.",
            "So what these novel biotherapy?"
        ],
        [
            "Take modalities and technology technological give us is GNU solution to to address the unmet medical need we still have today.",
            "Now, there are fundamental challenges with that to what I said before on the scientific side, you know the pharmacology of these compounds is poorly or in some cases completely not understood.",
            "But also we have to see it from a competition side.",
            "The number of targets is limited with the current knowledge we have, so there are many companies actually going after the very same target.",
            "And then you have also the corporate organization as a challenge itself, because data is generated in many different labs in their many different departments and for optimal decision making, development data sharing has to be established.",
            "It data has to be integrated to get to robust the decision making.",
            "So the challenge here is how can we inform.",
            "Sooo in decision making for things like target assessment, selection of the modality that is, the format, the compound design because we need to define what affinity this compound should have binding violence.",
            "See what antibody toxin combination we want to take so many designs.",
            "The options you need to decide on you need to select from the candidates.",
            "You then generate and then you need to translate these compounds from animal to human and you need to think about toxicity and dozing regimen selection.",
            "And with in mind what you actually want to do is to bring the most competitive drug to patients, so we need to solve 2 problems, one having a competitive drug and then also meet an unmet medical need.",
            "And here is where systems pharmacology can bring a small contribution to this set of problems as a quantitative tool which can integrate data and convert it to to knowledge.",
            "So let me."
        ],
        [
            "Tell you a little bit something about what systems pharmacology is and where we can position it relative to the other.",
            "Silicone methods we have in sort of the preclinical.",
            "In clinical PK PD space.",
            "Interesting, really.",
            "I think systems Pharmacology is is more of an industry tool rather than an academic tool.",
            "I think it really got created informed through the very specific needs we have in drug development.",
            "So what we of course have is pharmacometrics sort of the conventional PK PD modeling as a tool.",
            "It's established it has shown tremendous value to drug development and what it is essentially describes.",
            "It tries to describe the concentration of a compound in plasma and link it to a clinical endpoint, and typically statistical models are used, so there is no mechanism behind that.",
            "One advantage of that is depending on that on the data.",
            "This model can be very accurate.",
            "The drawback is if you try to extrapolate, if you try to ask questions which go beyond what your data is covering.",
            "So if you try to extrapolate, these models are not reliable because you're using statistical fits, regression lines and you don't know how to biological or the pharmacokinetics might behave if you take yet in a higher dose or or change any other parameter.",
            "So that's that's form metrics.",
            "Also important.",
            "Understand here.",
            "They're available tools which are qualified which are available.",
            "They have industry quality standards and so if you want to do that, you can you know select right product and get involved into this type of approach.",
            "On the other extreme, we have systems biology which has quite a history.",
            "It has been also applied in drug discovery and preclinical development.",
            "But I have to say.",
            "It has little documented value for drug development.",
            "It's different too too.",
            "Too academic research for systems biology really has shown a value as a additional tool too wet to living sort of experimental work.",
            "The difference here with systems budget really just focus on on the cell on the cell level, right?",
            "It's looking at biological pathways, so there is no natural link actually to pharmacological therapies here.",
            "The intent is to understand the molecular and cell biology.",
            "It's it's in many cases purely mechanistic, and because of that, if we have the right model, it's also very strong in able to make prediction of things you have not yet observed in your experiments.",
            "That's the true power of systems biology.",
            "Disadvantages can be hugely complex, right?",
            "Because there's so many biological components you need to put them all in, you don't know where to stop.",
            "And also there are actually few or I would say none industry standard.",
            "Tools program software you can rely on to take this approach, and So what?",
            "What was created, I think is now where the industry is slowly heading into systems pharmacology approach which is trying to put together 2 advantages of these approaches so you know you're still having the PK PD particle at the center at the core with looking sort of what is happening in an animal or inpatient.",
            "You're considering tissues.",
            "You're considering the patient and population.",
            "But you know you extend it.",
            "You are not only interested in plasma, but really on the side of action.",
            "Would you try to think about the Physiology and what it ends up is?",
            "It's a semi mechanistic approach, so you try to put some Revel relevant mechanism into it.",
            "But you say I can't go too far.",
            "So at some point I have to stop and I have to put some statistic assumption in there.",
            "So it can be accurate at the same time as as well as predictive.",
            "The disadvantage is not yet established, but it's slowly going there.",
            "It has a large potential value and there are already tools available to engage in this type of approach."
        ],
        [
            "So what can you do?",
            "You know it as a tool.",
            "It can address the complexity or in PK PD of normal therapeutics it can integrate the kinetic compounds with biology biology so it can link sort of the DPK with target binding and downstream pharmacological effects.",
            "It allows to integrate data in vitro data, animal data, human data integrated to provide you sort of more comprehensive understanding on your compound.",
            "It allows to compare against your own.",
            "Compounds against competitors.",
            "And then sort of sort of the typical questions as such as design of experiments.",
            "Early translation from animal to human.",
            "Justify those in to selection and dosing interval.",
            "The competition part I mentioned.",
            "You know it can be also seen as a tool within a Corporation to help to bring together different departments working on different bits and pieces of biotherapeutic compound.",
            "So just."
        ],
        [
            "To make it a bit more concrete, you know models always will be very specific to the question of the problem, but I think we still can provide something like a general picture of what systems pharmacology model could look like and what the main ingredients are so it really tries to connect the delivery with with an effect on.",
            "The effect could be clinical effect, for it could be an effect on the biomarker on the left side.",
            "You have the pharmacokinetics with the distribution tissue axis.",
            "Ways of clearances which could be also receptor mediated.",
            "For example on the right side you have.",
            "In a way, the mirror of it just looking at at the targets you are asking.",
            "Worst target expressed.",
            "What is the mechanism of expression?",
            "If it's a soluble molecule, how does it distribute?",
            "If its receptor, what's the number on the cell?",
            "What cell types are rate was?",
            "What is the internalization mechanism?",
            "Can it be stimulated in some cases?",
            "No, doesn't get stored and so on and then connect it with the binding with the binding modality between the two and importantly also try to consider of course time so where it's a kinetic problem but also you look at issues absolutely critical.",
            "You know concentrations are not going to be the same in plasma as in the relevant issue where the site of action is in many cases.",
            "And also in some cases you might also include between patient variability because that's a very important factor.",
            "So you know that's something that's like a prototype systems pharmacology model."
        ],
        [
            "You know to the tools, so you also need some some software to to.",
            "To work on it, to to be able an in that specific foreign industry setting, you know you have criterias, you have limitations, you have regulatory requirements, legal requirements, time pressure, and so on.",
            "So you need to rely on some commercial tools which sort of can guarantee a certain level of quality, which also includes.",
            "Things like documentation, help line and so on.",
            "So very practical things.",
            "There is now actually quite a number of different solutions available.",
            "This is just a personal choice we have been developing over many years.",
            "The problem has always been that these softwares often just cover a very specific problem, so they would do parameter estimation for in a population.",
            "Context, but then you cannot sort of look at complex systems.",
            "So what we also did here is trying to develop something which is integrated so where it can take outputs from one system and directly have it input as an input in another software system."
        ],
        [
            "So let me give you just a small example here of what type of question you can answer or tackle with.",
            "With such an approach.",
            "And you know, really, the problem in fact is working in a company.",
            "It's quite difficult to come up with examples because it's all sort of a not not made for publicity error for public.",
            "So that's always sort of a challenge, but you know that sort of thing that exemplifies the use of it.",
            "So we're looking here at trying to come up with a design for a monoclonal antibody against dengue.",
            "Dangy basically say is a viral infection which is transmitted through mosquitoes.",
            "So divide you, you have an infection through through the skin.",
            "Go through an incubation time and then you get into an active.",
            "Where you develop strong fever and then you have two sort of scenarios.",
            "You can end up into.",
            "You can either recover slowly or you actually can depending on the virus levels you have in the blood you can develop very severe.",
            "Fever, internal bleeding, and basically a collapse of your.",
            "System which leads to death.",
            "So the goal here is sort of to develop something which can, you know, help you sort of to get into the recovery path instead of the more fatal one."
        ],
        [
            "So this problem was sort of.",
            "Model data semi mechanistic level which includes the virus as it distributes from the skin, the lymphatic system into blood and potentially into sort of surrounding tissues.",
            "The same is valid for the antibody which can distribute into different issues and then interact with the virus, and then you have to host the host cells.",
            "Off the virus which causes circulate in the blood and also exchange are in an exchange with the tissue and all these components are interacting.",
            "The interesting thing is it's quite a simple model, but if you put it up and you look at all the connections and possible transitions, it already becomes quite quite complex."
        ],
        [
            "So what we simulated or the scenario we looked at?",
            "That does have a laser, right?",
            "Does it?",
            "Is here so we're looking basically so the viraemia is just a number of virus particles you have in blood at infection.",
            "You know you get the replication of the virus, it gets detected.",
            "In in a clinic and this is where you start with the treatment you you give a single dose of the antibody and you wait for a week and then you do an assessment and you look at the levels of our EMEA relative to the case where you would not have treated the patient.",
            "So you have a basic dose response curve here with the number of virus particles in blood versus those.",
            "At this point in time, so you see, you need to give a high enough dose to have an effect, and also we have here different affinity's of the antibody and you can see the more affinity you have, the higher the affinity.",
            "Sort of, the more potent the antibody is.",
            "However, there is a limitation to that, so you run into saturation, so there's no reason to go beyond a certain critical affinity.",
            "But interesting Lee, you can also look at the run rate of the antibody, which is part of the affinity.",
            "On right is tells you how quickly the antibody can bind to the virus.",
            "If it's 10, fold higher, you get even as strong or shift of the dose response curve.",
            "Towards smaller doses and so have a more potent antibody.",
            "The nice thing is now actually that."
        ],
        [
            "Can put that into context and try to think why.",
            "Is that an explanation is actually quite simple, but somehow you have to make that step.",
            "Of course you're in a race where the virus is trying to infect the host cell, and you know once it does it you there's nothing you can do with an antibody.",
            "It's too late.",
            "So actually, with your therapeutic you need to be faster in binding the vice.",
            "Errors before it actually can infect the cell, so it's a question of how rapid the antibody is, and that's something you can actually design and select in the way you mature the antibody and that gives you a guidance in how to design, how to select antibodies out of what you are producing, and also helps you to rank and select relative to competitive through therapy.",
            "Competitors for example, already on the market.",
            "This result has been sort of reproduced experimentally with a different antibody against a different virus, but it's the same sort of set up right.",
            "You have a virus and an antibody.",
            "This one, this palivizumab is actually on the market and they tried different variants in what they found out is really that an improvement of the onrait will provide you an improvement.",
            "Relative to two sort of the original compound."
        ],
        [
            "OK, so.",
            "Now if we try to think about vision for systems pharmacology in in an industry setting.",
            "It's what we want to do is to to engineer biomolecules to obtain better drugs for patients and better differentiation against competitors were basically trying to do the same, so we want to design for Superior peak properties, select and validate the best candidates and also advise on experimental and animal to human translational strategies.",
            "The what the things.",
            "So there needs to be a few things to be put into place to to sort of move towards that.",
            "That vision one is that as an in silico approach, and I think that's important because that has been maybe confused in the past.",
            "What we're good at is at engineering.",
            "So given for system where we know the parts, we can actually model this system and predict the emerging properties of it.",
            "And that's in a way, an engineering approach.",
            "You take known elements and you put them together.",
            "We're not good at discovery, you know, I think this covers something where you need the experiment.",
            "You need to have the substance, the cells, the animal, the microscope, and that's where you can discover.",
            "But really, what we try to need to focus then is the engineering approach where we take what we know, put it together in a model, and then use this model to inform experiments, decision criteria, selection and so on.",
            "To do that, we need to have the computational tools to within an industry setting to make sure we have the quality.",
            "With that we have the execution suite to interact with with the teams who are working at a high pace and are making decisions.",
            "Um?",
            "And that's not only the case for."
        ],
        [
            "For for, for software tools I will.",
            "I will talk to that right in a second so.",
            "In summary, no.",
            "To some of the challenges we have, you know it's one is the upscaling systems.",
            "Pharmacology is used in pockets.",
            "You know how can we upscale that approach to be more used in as a general solution?",
            "How can we collect the right data?",
            "It's still a challenge.",
            "You know plasma is a very or blood is very accessible.",
            "Compartment, but for many diseases it's not as relevant.",
            "How to overcome that that hurdle?",
            "How can you capture the value of it?",
            "You know if you achieve something in particular within sort of an industry setting, how can it be published?",
            "How it can be demonstrated that it brings through value?",
            "And with that, because you need to convince your leadership that it's something meaningful, otherwise they will ask, you know what's the same time savings?",
            "What's money savings?",
            "And if you cannot answer that question, we have a hard time to convince anyone.",
            "Also, on the people side, and that's towards more of the academic.",
            "So this approach needs right.",
            "People with the right educational background.",
            "Currently people are coming from many different fields an are trained on the job.",
            "That's the situation today, and there are only a few programs in some places trying or sort of now establishing systems from ecology, educational programs.",
            "Just that's sort of an anecdote."
        ],
        [
            "And at the end, just imagine that as company you want to engage in developing a treatment for diabetes, you consider you know it's a well studied, diseased.",
            "A lot of details are known about it and so you think we, let's say you're modeling systems pharmacology approach to address some of the questions here.",
            "And there are databases where you have corrected models and you go into there and you have something like 1000 models on diabetes.",
            "So you know what are you doing with it?",
            "I mean, it's completely useless.",
            "I mean it will take you so long to go through them, understand what is the level of quality, what question do they address, what is missing, what version is it an?",
            "Can I use it for my question, it's just not at the level where we basically can really use it to address a question within an industrial setting.",
            "So some step between this enormous knowledge which is in here because I'm sure you know a lot of thought.",
            "And great work has been done on these models.",
            "Just the usefulness for someone coming and trying to apply them is quite low at this point in time.",
            "So with this I'd like to finish my presentation here and."
        ],
        [
            "I'll be happy to answer a few questions if we have time.",
            "OK, great.",
            "Thank you.",
            "Pointed out that it's not always easy to get concentration at the target sites with this modeling techniques, which are more data driven.",
            "So do you have an idea what other modeling techniques could be used to overcome that issue?",
            "Well, well, I'm not sure it's really.",
            "It's a fundamental problem, right?",
            "If you're working.",
            "On a disease which is basically highly localized in tissues which are difficult, I think the brain is is a very good example or anything related to the spinal cord or any most of the organ related diseases to long.",
            "For example, if you start to use for example, this ball measurements from the lung or you know kind of sputum and you use it within a model framework where you really need to have.",
            "Accurate measurements and you need to understand how this measurement is created.",
            "What is the process of this concentration in this sputum, and how does it relate to a local concentration in the lung lining you realize that there are so many questions to that value to that measurements that actually for modeling it has a very challenging use.",
            "And So what I think needs to be established, or really new ways of trying to measure in human which are, you know, standardized, reproducible, an are getting more too.",
            "Side of action."
        ]
    ],
    "summarization": {
        "clip_0": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Good afternoon everyone.",
                    "label": 0
                },
                {
                    "sent": "I'd like to thank the organizers very much.",
                    "label": 0
                },
                {
                    "sent": "Give me the opportunity here to present at this conference in front of this audience.",
                    "label": 0
                },
                {
                    "sent": "So I think it's going to be a little bit on uphill talk for me because I'm going to present an industry perspective on an in silico approach on biotherapeutics, so it's three Rs.",
                    "label": 1
                },
                {
                    "sent": "I would think that this audience is probably a bit further away to what I heard this morning, so let's see how how this will work.",
                    "label": 0
                }
            ]
        },
        "clip_1": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "If we look at the current landscape in drug development or the IT really broadened from the original small molecule approach and what we have of course antibodies but also that sort development to continue to grow, we have different approaches.",
                    "label": 0
                },
                {
                    "sent": "We have BI specifics with the different derivatives, we have, fat fragments, single chain of fees we have non aborted so.",
                    "label": 0
                },
                {
                    "sent": "Immune components from other animal species which might have which might have other favorable properties.",
                    "label": 0
                },
                {
                    "sent": "We of course also have S RNA based therapeutics or cell based therapeutics, so the whole thing tremendously grew in the past years.",
                    "label": 0
                },
                {
                    "sent": "And what actually?",
                    "label": 0
                },
                {
                    "sent": "What is a great achievement?",
                    "label": 0
                },
                {
                    "sent": "And development is also a challenge.",
                    "label": 0
                },
                {
                    "sent": "At the same time.",
                    "label": 0
                },
                {
                    "sent": "Because the question always, you know, given given a tour.",
                    "label": 0
                }
            ]
        },
        "clip_2": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Git or a goal we like to achieve what is then the the right approach to land on on the target, literally on the target molecule.",
                    "label": 0
                },
                {
                    "sent": "We want to want to do.",
                    "label": 0
                },
                {
                    "sent": "We want to focus on.",
                    "label": 0
                },
                {
                    "sent": "Now you suddenly have a big choice of different approaches, and of course what I want.",
                    "label": 0
                },
                {
                    "sent": "Forgot to mention, we have also the combination of antibodies with more small molecules with toxins.",
                    "label": 0
                },
                {
                    "sent": "Unable to drag Queen if it's for an therapeutic approach to cancer.",
                    "label": 0
                },
                {
                    "sent": "And of course, you know you won't be.",
                    "label": 0
                },
                {
                    "sent": "It will not be possible to screen through all the different formats to screen all the different properties of each of these formats to figure out what the best approach is, so there needs to be some better, some more rational approach in selecting, developing and selecting the right molecule.",
                    "label": 0
                },
                {
                    "sent": "So what these novel biotherapy?",
                    "label": 0
                }
            ]
        },
        "clip_3": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Take modalities and technology technological give us is GNU solution to to address the unmet medical need we still have today.",
                    "label": 0
                },
                {
                    "sent": "Now, there are fundamental challenges with that to what I said before on the scientific side, you know the pharmacology of these compounds is poorly or in some cases completely not understood.",
                    "label": 1
                },
                {
                    "sent": "But also we have to see it from a competition side.",
                    "label": 0
                },
                {
                    "sent": "The number of targets is limited with the current knowledge we have, so there are many companies actually going after the very same target.",
                    "label": 1
                },
                {
                    "sent": "And then you have also the corporate organization as a challenge itself, because data is generated in many different labs in their many different departments and for optimal decision making, development data sharing has to be established.",
                    "label": 0
                },
                {
                    "sent": "It data has to be integrated to get to robust the decision making.",
                    "label": 1
                },
                {
                    "sent": "So the challenge here is how can we inform.",
                    "label": 1
                },
                {
                    "sent": "Sooo in decision making for things like target assessment, selection of the modality that is, the format, the compound design because we need to define what affinity this compound should have binding violence.",
                    "label": 0
                },
                {
                    "sent": "See what antibody toxin combination we want to take so many designs.",
                    "label": 0
                },
                {
                    "sent": "The options you need to decide on you need to select from the candidates.",
                    "label": 0
                },
                {
                    "sent": "You then generate and then you need to translate these compounds from animal to human and you need to think about toxicity and dozing regimen selection.",
                    "label": 0
                },
                {
                    "sent": "And with in mind what you actually want to do is to bring the most competitive drug to patients, so we need to solve 2 problems, one having a competitive drug and then also meet an unmet medical need.",
                    "label": 1
                },
                {
                    "sent": "And here is where systems pharmacology can bring a small contribution to this set of problems as a quantitative tool which can integrate data and convert it to to knowledge.",
                    "label": 0
                },
                {
                    "sent": "So let me.",
                    "label": 0
                }
            ]
        },
        "clip_4": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Tell you a little bit something about what systems pharmacology is and where we can position it relative to the other.",
                    "label": 0
                },
                {
                    "sent": "Silicone methods we have in sort of the preclinical.",
                    "label": 0
                },
                {
                    "sent": "In clinical PK PD space.",
                    "label": 0
                },
                {
                    "sent": "Interesting, really.",
                    "label": 0
                },
                {
                    "sent": "I think systems Pharmacology is is more of an industry tool rather than an academic tool.",
                    "label": 0
                },
                {
                    "sent": "I think it really got created informed through the very specific needs we have in drug development.",
                    "label": 0
                },
                {
                    "sent": "So what we of course have is pharmacometrics sort of the conventional PK PD modeling as a tool.",
                    "label": 0
                },
                {
                    "sent": "It's established it has shown tremendous value to drug development and what it is essentially describes.",
                    "label": 0
                },
                {
                    "sent": "It tries to describe the concentration of a compound in plasma and link it to a clinical endpoint, and typically statistical models are used, so there is no mechanism behind that.",
                    "label": 0
                },
                {
                    "sent": "One advantage of that is depending on that on the data.",
                    "label": 0
                },
                {
                    "sent": "This model can be very accurate.",
                    "label": 1
                },
                {
                    "sent": "The drawback is if you try to extrapolate, if you try to ask questions which go beyond what your data is covering.",
                    "label": 0
                },
                {
                    "sent": "So if you try to extrapolate, these models are not reliable because you're using statistical fits, regression lines and you don't know how to biological or the pharmacokinetics might behave if you take yet in a higher dose or or change any other parameter.",
                    "label": 0
                },
                {
                    "sent": "So that's that's form metrics.",
                    "label": 0
                },
                {
                    "sent": "Also important.",
                    "label": 0
                },
                {
                    "sent": "Understand here.",
                    "label": 0
                },
                {
                    "sent": "They're available tools which are qualified which are available.",
                    "label": 0
                },
                {
                    "sent": "They have industry quality standards and so if you want to do that, you can you know select right product and get involved into this type of approach.",
                    "label": 0
                },
                {
                    "sent": "On the other extreme, we have systems biology which has quite a history.",
                    "label": 1
                },
                {
                    "sent": "It has been also applied in drug discovery and preclinical development.",
                    "label": 0
                },
                {
                    "sent": "But I have to say.",
                    "label": 0
                },
                {
                    "sent": "It has little documented value for drug development.",
                    "label": 1
                },
                {
                    "sent": "It's different too too.",
                    "label": 0
                },
                {
                    "sent": "Too academic research for systems biology really has shown a value as a additional tool too wet to living sort of experimental work.",
                    "label": 0
                },
                {
                    "sent": "The difference here with systems budget really just focus on on the cell on the cell level, right?",
                    "label": 0
                },
                {
                    "sent": "It's looking at biological pathways, so there is no natural link actually to pharmacological therapies here.",
                    "label": 1
                },
                {
                    "sent": "The intent is to understand the molecular and cell biology.",
                    "label": 0
                },
                {
                    "sent": "It's it's in many cases purely mechanistic, and because of that, if we have the right model, it's also very strong in able to make prediction of things you have not yet observed in your experiments.",
                    "label": 0
                },
                {
                    "sent": "That's the true power of systems biology.",
                    "label": 0
                },
                {
                    "sent": "Disadvantages can be hugely complex, right?",
                    "label": 0
                },
                {
                    "sent": "Because there's so many biological components you need to put them all in, you don't know where to stop.",
                    "label": 0
                },
                {
                    "sent": "And also there are actually few or I would say none industry standard.",
                    "label": 0
                },
                {
                    "sent": "Tools program software you can rely on to take this approach, and So what?",
                    "label": 1
                },
                {
                    "sent": "What was created, I think is now where the industry is slowly heading into systems pharmacology approach which is trying to put together 2 advantages of these approaches so you know you're still having the PK PD particle at the center at the core with looking sort of what is happening in an animal or inpatient.",
                    "label": 0
                },
                {
                    "sent": "You're considering tissues.",
                    "label": 0
                },
                {
                    "sent": "You're considering the patient and population.",
                    "label": 0
                },
                {
                    "sent": "But you know you extend it.",
                    "label": 0
                },
                {
                    "sent": "You are not only interested in plasma, but really on the side of action.",
                    "label": 0
                },
                {
                    "sent": "Would you try to think about the Physiology and what it ends up is?",
                    "label": 1
                },
                {
                    "sent": "It's a semi mechanistic approach, so you try to put some Revel relevant mechanism into it.",
                    "label": 0
                },
                {
                    "sent": "But you say I can't go too far.",
                    "label": 0
                },
                {
                    "sent": "So at some point I have to stop and I have to put some statistic assumption in there.",
                    "label": 0
                },
                {
                    "sent": "So it can be accurate at the same time as as well as predictive.",
                    "label": 0
                },
                {
                    "sent": "The disadvantage is not yet established, but it's slowly going there.",
                    "label": 0
                },
                {
                    "sent": "It has a large potential value and there are already tools available to engage in this type of approach.",
                    "label": 0
                }
            ]
        },
        "clip_5": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So what can you do?",
                    "label": 0
                },
                {
                    "sent": "You know it as a tool.",
                    "label": 0
                },
                {
                    "sent": "It can address the complexity or in PK PD of normal therapeutics it can integrate the kinetic compounds with biology biology so it can link sort of the DPK with target binding and downstream pharmacological effects.",
                    "label": 1
                },
                {
                    "sent": "It allows to integrate data in vitro data, animal data, human data integrated to provide you sort of more comprehensive understanding on your compound.",
                    "label": 0
                },
                {
                    "sent": "It allows to compare against your own.",
                    "label": 0
                },
                {
                    "sent": "Compounds against competitors.",
                    "label": 1
                },
                {
                    "sent": "And then sort of sort of the typical questions as such as design of experiments.",
                    "label": 0
                },
                {
                    "sent": "Early translation from animal to human.",
                    "label": 1
                },
                {
                    "sent": "Justify those in to selection and dosing interval.",
                    "label": 0
                },
                {
                    "sent": "The competition part I mentioned.",
                    "label": 0
                },
                {
                    "sent": "You know it can be also seen as a tool within a Corporation to help to bring together different departments working on different bits and pieces of biotherapeutic compound.",
                    "label": 0
                },
                {
                    "sent": "So just.",
                    "label": 0
                }
            ]
        },
        "clip_6": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "To make it a bit more concrete, you know models always will be very specific to the question of the problem, but I think we still can provide something like a general picture of what systems pharmacology model could look like and what the main ingredients are so it really tries to connect the delivery with with an effect on.",
                    "label": 0
                },
                {
                    "sent": "The effect could be clinical effect, for it could be an effect on the biomarker on the left side.",
                    "label": 0
                },
                {
                    "sent": "You have the pharmacokinetics with the distribution tissue axis.",
                    "label": 1
                },
                {
                    "sent": "Ways of clearances which could be also receptor mediated.",
                    "label": 0
                },
                {
                    "sent": "For example on the right side you have.",
                    "label": 0
                },
                {
                    "sent": "In a way, the mirror of it just looking at at the targets you are asking.",
                    "label": 0
                },
                {
                    "sent": "Worst target expressed.",
                    "label": 0
                },
                {
                    "sent": "What is the mechanism of expression?",
                    "label": 0
                },
                {
                    "sent": "If it's a soluble molecule, how does it distribute?",
                    "label": 0
                },
                {
                    "sent": "If its receptor, what's the number on the cell?",
                    "label": 0
                },
                {
                    "sent": "What cell types are rate was?",
                    "label": 0
                },
                {
                    "sent": "What is the internalization mechanism?",
                    "label": 0
                },
                {
                    "sent": "Can it be stimulated in some cases?",
                    "label": 0
                },
                {
                    "sent": "No, doesn't get stored and so on and then connect it with the binding with the binding modality between the two and importantly also try to consider of course time so where it's a kinetic problem but also you look at issues absolutely critical.",
                    "label": 0
                },
                {
                    "sent": "You know concentrations are not going to be the same in plasma as in the relevant issue where the site of action is in many cases.",
                    "label": 0
                },
                {
                    "sent": "And also in some cases you might also include between patient variability because that's a very important factor.",
                    "label": 0
                },
                {
                    "sent": "So you know that's something that's like a prototype systems pharmacology model.",
                    "label": 1
                }
            ]
        },
        "clip_7": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "You know to the tools, so you also need some some software to to.",
                    "label": 0
                },
                {
                    "sent": "To work on it, to to be able an in that specific foreign industry setting, you know you have criterias, you have limitations, you have regulatory requirements, legal requirements, time pressure, and so on.",
                    "label": 0
                },
                {
                    "sent": "So you need to rely on some commercial tools which sort of can guarantee a certain level of quality, which also includes.",
                    "label": 0
                },
                {
                    "sent": "Things like documentation, help line and so on.",
                    "label": 0
                },
                {
                    "sent": "So very practical things.",
                    "label": 0
                },
                {
                    "sent": "There is now actually quite a number of different solutions available.",
                    "label": 0
                },
                {
                    "sent": "This is just a personal choice we have been developing over many years.",
                    "label": 0
                },
                {
                    "sent": "The problem has always been that these softwares often just cover a very specific problem, so they would do parameter estimation for in a population.",
                    "label": 1
                },
                {
                    "sent": "Context, but then you cannot sort of look at complex systems.",
                    "label": 1
                },
                {
                    "sent": "So what we also did here is trying to develop something which is integrated so where it can take outputs from one system and directly have it input as an input in another software system.",
                    "label": 0
                }
            ]
        },
        "clip_8": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So let me give you just a small example here of what type of question you can answer or tackle with.",
                    "label": 0
                },
                {
                    "sent": "With such an approach.",
                    "label": 0
                },
                {
                    "sent": "And you know, really, the problem in fact is working in a company.",
                    "label": 0
                },
                {
                    "sent": "It's quite difficult to come up with examples because it's all sort of a not not made for publicity error for public.",
                    "label": 0
                },
                {
                    "sent": "So that's always sort of a challenge, but you know that sort of thing that exemplifies the use of it.",
                    "label": 0
                },
                {
                    "sent": "So we're looking here at trying to come up with a design for a monoclonal antibody against dengue.",
                    "label": 0
                },
                {
                    "sent": "Dangy basically say is a viral infection which is transmitted through mosquitoes.",
                    "label": 0
                },
                {
                    "sent": "So divide you, you have an infection through through the skin.",
                    "label": 0
                },
                {
                    "sent": "Go through an incubation time and then you get into an active.",
                    "label": 0
                },
                {
                    "sent": "Where you develop strong fever and then you have two sort of scenarios.",
                    "label": 0
                },
                {
                    "sent": "You can end up into.",
                    "label": 0
                },
                {
                    "sent": "You can either recover slowly or you actually can depending on the virus levels you have in the blood you can develop very severe.",
                    "label": 0
                },
                {
                    "sent": "Fever, internal bleeding, and basically a collapse of your.",
                    "label": 0
                },
                {
                    "sent": "System which leads to death.",
                    "label": 0
                },
                {
                    "sent": "So the goal here is sort of to develop something which can, you know, help you sort of to get into the recovery path instead of the more fatal one.",
                    "label": 0
                }
            ]
        },
        "clip_9": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So this problem was sort of.",
                    "label": 0
                },
                {
                    "sent": "Model data semi mechanistic level which includes the virus as it distributes from the skin, the lymphatic system into blood and potentially into sort of surrounding tissues.",
                    "label": 0
                },
                {
                    "sent": "The same is valid for the antibody which can distribute into different issues and then interact with the virus, and then you have to host the host cells.",
                    "label": 0
                },
                {
                    "sent": "Off the virus which causes circulate in the blood and also exchange are in an exchange with the tissue and all these components are interacting.",
                    "label": 0
                },
                {
                    "sent": "The interesting thing is it's quite a simple model, but if you put it up and you look at all the connections and possible transitions, it already becomes quite quite complex.",
                    "label": 0
                }
            ]
        },
        "clip_10": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So what we simulated or the scenario we looked at?",
                    "label": 0
                },
                {
                    "sent": "That does have a laser, right?",
                    "label": 0
                },
                {
                    "sent": "Does it?",
                    "label": 0
                },
                {
                    "sent": "Is here so we're looking basically so the viraemia is just a number of virus particles you have in blood at infection.",
                    "label": 0
                },
                {
                    "sent": "You know you get the replication of the virus, it gets detected.",
                    "label": 0
                },
                {
                    "sent": "In in a clinic and this is where you start with the treatment you you give a single dose of the antibody and you wait for a week and then you do an assessment and you look at the levels of our EMEA relative to the case where you would not have treated the patient.",
                    "label": 0
                },
                {
                    "sent": "So you have a basic dose response curve here with the number of virus particles in blood versus those.",
                    "label": 0
                },
                {
                    "sent": "At this point in time, so you see, you need to give a high enough dose to have an effect, and also we have here different affinity's of the antibody and you can see the more affinity you have, the higher the affinity.",
                    "label": 0
                },
                {
                    "sent": "Sort of, the more potent the antibody is.",
                    "label": 0
                },
                {
                    "sent": "However, there is a limitation to that, so you run into saturation, so there's no reason to go beyond a certain critical affinity.",
                    "label": 0
                },
                {
                    "sent": "But interesting Lee, you can also look at the run rate of the antibody, which is part of the affinity.",
                    "label": 0
                },
                {
                    "sent": "On right is tells you how quickly the antibody can bind to the virus.",
                    "label": 0
                },
                {
                    "sent": "If it's 10, fold higher, you get even as strong or shift of the dose response curve.",
                    "label": 0
                },
                {
                    "sent": "Towards smaller doses and so have a more potent antibody.",
                    "label": 0
                },
                {
                    "sent": "The nice thing is now actually that.",
                    "label": 0
                }
            ]
        },
        "clip_11": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Can put that into context and try to think why.",
                    "label": 0
                },
                {
                    "sent": "Is that an explanation is actually quite simple, but somehow you have to make that step.",
                    "label": 0
                },
                {
                    "sent": "Of course you're in a race where the virus is trying to infect the host cell, and you know once it does it you there's nothing you can do with an antibody.",
                    "label": 0
                },
                {
                    "sent": "It's too late.",
                    "label": 0
                },
                {
                    "sent": "So actually, with your therapeutic you need to be faster in binding the vice.",
                    "label": 0
                },
                {
                    "sent": "Errors before it actually can infect the cell, so it's a question of how rapid the antibody is, and that's something you can actually design and select in the way you mature the antibody and that gives you a guidance in how to design, how to select antibodies out of what you are producing, and also helps you to rank and select relative to competitive through therapy.",
                    "label": 0
                },
                {
                    "sent": "Competitors for example, already on the market.",
                    "label": 0
                },
                {
                    "sent": "This result has been sort of reproduced experimentally with a different antibody against a different virus, but it's the same sort of set up right.",
                    "label": 0
                },
                {
                    "sent": "You have a virus and an antibody.",
                    "label": 0
                },
                {
                    "sent": "This one, this palivizumab is actually on the market and they tried different variants in what they found out is really that an improvement of the onrait will provide you an improvement.",
                    "label": 0
                },
                {
                    "sent": "Relative to two sort of the original compound.",
                    "label": 0
                }
            ]
        },
        "clip_12": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "OK, so.",
                    "label": 0
                },
                {
                    "sent": "Now if we try to think about vision for systems pharmacology in in an industry setting.",
                    "label": 0
                },
                {
                    "sent": "It's what we want to do is to to engineer biomolecules to obtain better drugs for patients and better differentiation against competitors were basically trying to do the same, so we want to design for Superior peak properties, select and validate the best candidates and also advise on experimental and animal to human translational strategies.",
                    "label": 1
                },
                {
                    "sent": "The what the things.",
                    "label": 0
                },
                {
                    "sent": "So there needs to be a few things to be put into place to to sort of move towards that.",
                    "label": 0
                },
                {
                    "sent": "That vision one is that as an in silico approach, and I think that's important because that has been maybe confused in the past.",
                    "label": 0
                },
                {
                    "sent": "What we're good at is at engineering.",
                    "label": 0
                },
                {
                    "sent": "So given for system where we know the parts, we can actually model this system and predict the emerging properties of it.",
                    "label": 0
                },
                {
                    "sent": "And that's in a way, an engineering approach.",
                    "label": 0
                },
                {
                    "sent": "You take known elements and you put them together.",
                    "label": 0
                },
                {
                    "sent": "We're not good at discovery, you know, I think this covers something where you need the experiment.",
                    "label": 0
                },
                {
                    "sent": "You need to have the substance, the cells, the animal, the microscope, and that's where you can discover.",
                    "label": 0
                },
                {
                    "sent": "But really, what we try to need to focus then is the engineering approach where we take what we know, put it together in a model, and then use this model to inform experiments, decision criteria, selection and so on.",
                    "label": 0
                },
                {
                    "sent": "To do that, we need to have the computational tools to within an industry setting to make sure we have the quality.",
                    "label": 0
                },
                {
                    "sent": "With that we have the execution suite to interact with with the teams who are working at a high pace and are making decisions.",
                    "label": 0
                },
                {
                    "sent": "Um?",
                    "label": 0
                },
                {
                    "sent": "And that's not only the case for.",
                    "label": 0
                }
            ]
        },
        "clip_13": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "For for, for software tools I will.",
                    "label": 0
                },
                {
                    "sent": "I will talk to that right in a second so.",
                    "label": 0
                },
                {
                    "sent": "In summary, no.",
                    "label": 0
                },
                {
                    "sent": "To some of the challenges we have, you know it's one is the upscaling systems.",
                    "label": 0
                },
                {
                    "sent": "Pharmacology is used in pockets.",
                    "label": 0
                },
                {
                    "sent": "You know how can we upscale that approach to be more used in as a general solution?",
                    "label": 1
                },
                {
                    "sent": "How can we collect the right data?",
                    "label": 1
                },
                {
                    "sent": "It's still a challenge.",
                    "label": 0
                },
                {
                    "sent": "You know plasma is a very or blood is very accessible.",
                    "label": 0
                },
                {
                    "sent": "Compartment, but for many diseases it's not as relevant.",
                    "label": 1
                },
                {
                    "sent": "How to overcome that that hurdle?",
                    "label": 0
                },
                {
                    "sent": "How can you capture the value of it?",
                    "label": 0
                },
                {
                    "sent": "You know if you achieve something in particular within sort of an industry setting, how can it be published?",
                    "label": 0
                },
                {
                    "sent": "How it can be demonstrated that it brings through value?",
                    "label": 0
                },
                {
                    "sent": "And with that, because you need to convince your leadership that it's something meaningful, otherwise they will ask, you know what's the same time savings?",
                    "label": 0
                },
                {
                    "sent": "What's money savings?",
                    "label": 0
                },
                {
                    "sent": "And if you cannot answer that question, we have a hard time to convince anyone.",
                    "label": 0
                },
                {
                    "sent": "Also, on the people side, and that's towards more of the academic.",
                    "label": 1
                },
                {
                    "sent": "So this approach needs right.",
                    "label": 0
                },
                {
                    "sent": "People with the right educational background.",
                    "label": 1
                },
                {
                    "sent": "Currently people are coming from many different fields an are trained on the job.",
                    "label": 0
                },
                {
                    "sent": "That's the situation today, and there are only a few programs in some places trying or sort of now establishing systems from ecology, educational programs.",
                    "label": 0
                },
                {
                    "sent": "Just that's sort of an anecdote.",
                    "label": 0
                }
            ]
        },
        "clip_14": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And at the end, just imagine that as company you want to engage in developing a treatment for diabetes, you consider you know it's a well studied, diseased.",
                    "label": 0
                },
                {
                    "sent": "A lot of details are known about it and so you think we, let's say you're modeling systems pharmacology approach to address some of the questions here.",
                    "label": 0
                },
                {
                    "sent": "And there are databases where you have corrected models and you go into there and you have something like 1000 models on diabetes.",
                    "label": 0
                },
                {
                    "sent": "So you know what are you doing with it?",
                    "label": 0
                },
                {
                    "sent": "I mean, it's completely useless.",
                    "label": 0
                },
                {
                    "sent": "I mean it will take you so long to go through them, understand what is the level of quality, what question do they address, what is missing, what version is it an?",
                    "label": 0
                },
                {
                    "sent": "Can I use it for my question, it's just not at the level where we basically can really use it to address a question within an industrial setting.",
                    "label": 0
                },
                {
                    "sent": "So some step between this enormous knowledge which is in here because I'm sure you know a lot of thought.",
                    "label": 0
                },
                {
                    "sent": "And great work has been done on these models.",
                    "label": 0
                },
                {
                    "sent": "Just the usefulness for someone coming and trying to apply them is quite low at this point in time.",
                    "label": 0
                },
                {
                    "sent": "So with this I'd like to finish my presentation here and.",
                    "label": 0
                }
            ]
        },
        "clip_15": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "I'll be happy to answer a few questions if we have time.",
                    "label": 0
                },
                {
                    "sent": "OK, great.",
                    "label": 0
                },
                {
                    "sent": "Thank you.",
                    "label": 0
                },
                {
                    "sent": "Pointed out that it's not always easy to get concentration at the target sites with this modeling techniques, which are more data driven.",
                    "label": 0
                },
                {
                    "sent": "So do you have an idea what other modeling techniques could be used to overcome that issue?",
                    "label": 0
                },
                {
                    "sent": "Well, well, I'm not sure it's really.",
                    "label": 0
                },
                {
                    "sent": "It's a fundamental problem, right?",
                    "label": 0
                },
                {
                    "sent": "If you're working.",
                    "label": 0
                },
                {
                    "sent": "On a disease which is basically highly localized in tissues which are difficult, I think the brain is is a very good example or anything related to the spinal cord or any most of the organ related diseases to long.",
                    "label": 0
                },
                {
                    "sent": "For example, if you start to use for example, this ball measurements from the lung or you know kind of sputum and you use it within a model framework where you really need to have.",
                    "label": 0
                },
                {
                    "sent": "Accurate measurements and you need to understand how this measurement is created.",
                    "label": 0
                },
                {
                    "sent": "What is the process of this concentration in this sputum, and how does it relate to a local concentration in the lung lining you realize that there are so many questions to that value to that measurements that actually for modeling it has a very challenging use.",
                    "label": 0
                },
                {
                    "sent": "And So what I think needs to be established, or really new ways of trying to measure in human which are, you know, standardized, reproducible, an are getting more too.",
                    "label": 0
                },
                {
                    "sent": "Side of action.",
                    "label": 0
                }
            ]
        }
    }
}